Charles River Executive and Leadership Team

Birgit Girshick, the Chief Executive Officer at Charles River, directs the overarching strategic vision for the organization. Overseeing the entire end-to-end portfolio, the Chief Executive Officer ensures that research, discovery, and safety assessment services meet the rigorous demands of global pharmaceutical and chemical clients. Girshick drives the expansion of scientific capabilities, maintaining a focus on accelerating the path from basic research to commercialization. By aligning internal resources with evolving regulatory landscapes, the Chief Executive Officer optimizes operational efficiency across all international sites. Birgit Girshick fosters a culture of innovation, enabling the company to support complex medical device development projects. This leadership role involves constant collaboration with the Board to secure long-term growth and market stability. Through precise execution of corporate objectives, Girshick maintains the company's position as a leader in the life sciences sector, consistently delivering value to patients and stakeholders worldwide.

Glenn Coleman, the Corporate Executive VP & Chief Financial Officer at Charles River, manages the financial health and capital allocation strategies of the organization. Overseeing global fiscal operations, the Corporate Executive VP & Chief Financial Officer ensures that investments in research, discovery, and manufacturing capabilities align with long-term growth targets. Coleman directs financial planning, reporting, and risk management, providing the necessary stability to support the company's expansive end-to-end portfolio. Glenn Coleman collaborates with the executive team to evaluate potential acquisitions and strategic partnerships that enhance the company's market position. By optimizing capital structure and maintaining rigorous financial controls, the Corporate Executive VP & Chief Financial Officer supports the delivery of high-value services to clients in the pharmaceutical and medical device industries. This leadership role involves constant monitoring of economic trends to ensure the company remains competitive on a global scale. Through disciplined financial stewardship, Coleman drives sustainable profitability and shareholder value.

Stacey Pauze, the Chief of Staff at Charles River, manages the synchronization of executive operations and strategic initiatives. Coordinating cross-functional workflows, the Chief of Staff ensures that leadership priorities align with the broader mission of accelerating drug and medical device development. Pauze facilitates communication between the C-suite and various business units, streamlining decision-making processes to enhance organizational agility. Stacey Pauze monitors the execution of key projects, identifying potential bottlenecks in the research and manufacturing pipeline. By maintaining oversight of administrative and operational functions, the Chief of Staff supports the seamless integration of global capacity and scientific advisory services. This role requires constant interaction with senior leadership to refine internal processes and improve overall productivity. Through meticulous planning and resource allocation, Pauze drives the operational excellence necessary to support the company's expansive portfolio, ensuring that every department contributes effectively to the overarching goal of bringing critical therapies to market.

Matthew Hewitt, the Vice President, Chief Technology Officer Manufacturing Business Division at Charles River, architects the technological infrastructure required for advanced manufacturing processes. Overseeing the integration of digital tools into the production of chemicals and medical devices, the Vice President, Chief Technology Officer Manufacturing Business Division ensures that manufacturing operations remain at the cutting edge of industry standards. Hewitt drives the implementation of scalable manufacturing solutions, supporting clients from initial research through to full-scale commercialization. Matthew Hewitt collaborates with scientific advisors to refine production methodologies, reducing time-to-market for essential medical products. By leveraging data-driven insights, the Vice President, Chief Technology Officer Manufacturing Business Division optimizes supply chain efficiency and quality control across global facilities. This leadership role involves managing complex technical teams to maintain regulatory compliance and operational excellence. Through continuous technological advancement, Hewitt secures the company's ability to meet the increasing demands of the global life sciences market.

Amy Cianciaruso, the Corporate Senior Vice President, Chief Communications Officer at Charles River, directs the global messaging and reputation management strategies for the company. Overseeing internal and external communications, the Corporate Senior Vice President, Chief Communications Officer ensures that the organization's mission to accelerate drug and medical device development remains clear to all stakeholders. Cianciaruso manages brand positioning, public relations, and corporate identity, fostering trust with clients, investors, and the scientific community. Amy Cianciaruso coordinates communication efforts across international regions, ensuring consistency in the company's narrative regarding its research and manufacturing capabilities. By developing comprehensive communication plans, the Corporate Senior Vice President, Chief Communications Officer supports the company's growth objectives and market influence. This leadership role involves close collaboration with other C-suite members to articulate the value of the company's integrated approach. Through strategic storytelling and transparent engagement, Cianciaruso strengthens the company's standing as a vital partner in the global healthcare ecosystem.